ESR1, ERBB2, and Ki67 MRNA Expression Predicts Stage and Grade of Non-muscle-invasive Bladder Carcinoma (NMIBC)

Overview

Journal Virchows Arch

Specialties Cell Biology
Molecular Biology
Pathology

Date 2016 Aug 13

PMID 27514658

Citations 22

Authors

Johannes Breyer

Ralph M Wirtz

Mark Laible

Kornelia Schlombs

Philipp Erben

Maximilian Christian Kriegmair

Robert Stoehr

Sebastian Eidt

Stefan Denzinger

Maximilian Burger

Arndt Hartmann

Wolfgang Otto

Affiliations

Soon will be listed here.

Abstract

Pathological staging and grading are crucial for risk assessment in non-muscle-invasive bladder cancer (NMIBC). Molecular grading might support pathological evaluation and minimize interobserver variability. In this study, the well-established breast cancer markers ESR1, PGR, ERBB2, and MKI67 were evaluated as potential molecular markers to support grading and staging in NMIBC. We retrospectively analyzed clinical data and formalin-fixed paraffin-embedded tissues (FFPE) of patients with NMIBC. Messenger RNA (mRNA) expression of the aforementioned markers was measured by single-step reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) using RNA-specific TaqMan assays. Relative gene expression was determined by normalization to two reference genes (CALM2 and B2M) using the 40 method and correlated to histopathological stage and grade. Pathological assessment was performed by an experienced uropathologist. Statistical analysis was performed using the SAS software JMP 9.0.0 version and GraphPad Prism 5.04. Of 381 cases of NMIBC, samples of 100 pTa and 255 pT1 cases were included in the final study. Spearman rank correlation revealed significant correlations between grade and expression of MKI67 (r = 0.52, p < 0.0001), ESR1 (r = 0.25, p < 0.0001), and ERBB2 (r = 0.18, p = 0.0008). In Mann-Whitney tests, MKI67 was significantly different between all grades (p < 0.0001), while ESR1 (p = 0.0006) and ERBB2 (p = 0.027) were significantly different between G2 and G3. Higher expression of MKI67 (r = 0.49; p < 0.0001), ERBB2 (r = 0.22; p < 0.0001), and ESR1 (r = 0.18; p = 0.0009) mRNA was positively correlated with higher stage. MKI67 (p < 0.0001), ERBB2 (p = 0.0058), and PGR (p = 0.0007) were significantly different between pTa and pT1. In NMIBC expression of ESR1, ERBB2 and MKI67 are significantly different between stage and grade. This potentially provides objective parameters for pathological evaluation.

Citing Articles

Predicting recurrence of non-muscle invasive bladder urothelial carcinoma: predictive value of the optimal cut-off value of Ki67.

Peng R, Zhang Y, Jia M, Yi X, Yi X, Li S Front Oncol. 2025; 14:1522009.

PMID: 39886663 PMC: 11779619. DOI: 10.3389/fonc.2024.1522009.

Mechanisms of Xiaozheng decoction for anti-bladder cancer effects via affecting the GSK3β/β-catenin signaling pathways: a network pharmacology-directed experimental investigation.

Zhuang J, Mo J, Huang Z, Yan Y, Wang Z, Cao X Chin Med. 2023; 18(1):104.

PMID: 37608369 PMC: 10464372. DOI: 10.1186/s13020-023-00818-5.

A transcriptional network of cell cycle dysregulation in noninvasive papillary urothelial carcinoma.

Warrick J, Knowles M, Hurst C, Shuman L, Raman J, Walter V Sci Rep. 2022; 12(1):16538.

PMID: 36192513 PMC: 9529892. DOI: 10.1038/s41598-022-20927-9.

Identification and Validation of N6-Methyladenosine-Related Biomarkers for Bladder Cancer: Implications for Immunotherapy.

Deng H, Tang F, Zhou M, Shan D, Chen X, Cao K Front Oncol. 2022; 12:820242.

PMID: 35311150 PMC: 8924666. DOI: 10.3389/fonc.2022.820242.

Identifying the Molecular Mechanisms Contributing to Progression, Metastasis, and Death in Low-grade Non-muscle-invasive Bladder Cancer: A Case Report.

Weiss S, Hallmann S, Koch S, Eidt S, Stoehr R, Veltrup E Eur Urol Open Sci. 2021; 27:29-32.

PMID: 34337514 PMC: 8317895. DOI: 10.1016/j.euros.2021.02.006.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Chen P, Yu H, Chang Y, Pan C . Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression. J Clin Pathol. 2012; 66(2):113-9. DOI: 10.1136/jclinpath-2012-200944. View

Hsu I, Vitkus S, Da J, Yeh S . Role of oestrogen receptors in bladder cancer development. Nat Rev Urol. 2013; 10(6):317-26. DOI: 10.1038/nrurol.2013.53. View

Otto W, Denzinger S, Fritsche H, Burger M, Wieland W, Hofstadter F . The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int. 2010; 107(3):404-8. DOI: 10.1111/j.1464-410X.2010.09515.x. View

Jalali Nadoushan M, Taheri T, Jouian N, Zaeri F . Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder. Urol J. 2007; 4(3):151-4. View

Babjuk M, Burger M, Zigeuner R, Shariat S, van Rhijn B, Comperat E . EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013; 64(4):639-53. DOI: 10.1016/j.eururo.2013.06.003. View

Lopez-Beltran A, Luque R, Alvarez-Kindelan J, Quintero A, Merlo F, Carrasco J . Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). Eur Urol. 2004; 45(5):606-12. DOI: 10.1016/j.eururo.2003.11.011. View

. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014; 507(7492):315-22. PMC: 3962515. DOI: 10.1038/nature12965. View

Rodriguez-Alonso A, Pita-Fernandez S, Gonzalez-Carrero J . p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma. Eur Urol. 2002; 41(2):182-8; discussion 188-9. DOI: 10.1016/s0302-2838(01)00038-0. View

10.

Amsellem-Ouazana D, Bieche I, Molinie V, Elie C, Vieillefond A, Tozlu S . Is quantitative real-time RT-PCR an adjunct to immunohistochemistry for the evaluation of ErbB2 status in transitional carcinoma of the bladder?. Eur Urol. 2006; 49(6):1035-42. DOI: 10.1016/j.eururo.2006.01.021. View

11.

Sylvester R, van der Meijden A, Oosterlinck W, Witjes J, Bouffioux C, Denis L . Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49(3):466-5. DOI: 10.1016/j.eururo.2005.12.031. View

12.

Rajjayabun P, Keegan P, Lunec J, Mellon J . erbB receptor expression patterns in human bladder cancer. Urology. 2005; 66(1):196-200. DOI: 10.1016/j.urology.2005.01.046. View

13.

Iyer G, Al-Ahmadie H, Schultz N, Hanrahan A, Ostrovnaya I, Balar A . Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol. 2013; 31(25):3133-40. PMC: 3753703. DOI: 10.1200/JCO.2012.46.5740. View

14.

Prout Jr G, Barton B, Griffin P, FRIEDELL G . Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group. J Urol. 1992; 148(5):1413-9. DOI: 10.1016/s0022-5347(17)36924-0. View

15.

Zhao J, Xu W, Zhang Z, Song R, Zeng S, Sun Y . Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. Int Urol Nephrol. 2014; 47(1):87-94. DOI: 10.1007/s11255-014-0866-z. View

16.

Tan W, Boorjian S, Advani P, Farmer S, Lohse C, Cheville J . The Estrogen Pathway: Estrogen Receptor-α, Progesterone Receptor, and Estrogen Receptor-β Expression in Radical Cystectomy Urothelial Cell Carcinoma Specimens. Clin Genitourin Cancer. 2015; 13(5):476-84. DOI: 10.1016/j.clgc.2015.04.001. View

17.

Otto W, Denzinger S, Fritsche H, Burger M, Rossler W, Bertz S . Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three.... Clin Genitourin Cancer. 2013; 11(4):537-44. DOI: 10.1016/j.clgc.2013.05.001. View

18.

Wang L, Feng C, Ding G, Ding Q, Zhou Z, Jiang H . Ki67 and TP53 expressions predict recurrence of non-muscle-invasive bladder cancer. Tumour Biol. 2013; 35(4):2989-95. DOI: 10.1007/s13277-013-1384-9. View

19.

Sjodahl G, Lauss M, Lovgren K, Chebil G, Gudjonsson S, Veerla S . A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012; 18(12):3377-86. DOI: 10.1158/1078-0432.CCR-12-0077-T. View

20.

Shen S, Smith C, Hsieh J, Yu J, Kim I, Jian W . Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer. 2006; 106(12):2610-6. DOI: 10.1002/cncr.21945. View